GAVI, the Vaccine Alliance

GAVI emerged at the turn of the millennium from a recognition that the vaccine market was failing the world's poorest children. While wealthy nations enjoyed access to an expanding portfolio of immunizations, developing countries lagged years or even decades behind in introducing new vaccines. The cost barrier was formidable, and pharmaceutical companies had little financial incentive to prioritize markets where governments could barely afford basic health infrastructure. This disparity meant that children in low-income countries faced dramatically higher risks of death from diseases that were easily preventable elsewhere.

The alliance was launched at the World Economic Forum in Davos in January 2000, bringing together an unprecedented coalition. The Bill & Melinda Gates Foundation provided crucial seed funding with an initial commitment of 750 million dollars over five years, signaling the potential for philanthropic capital to catalyze systemic change. Joining the partnership were the World Health Organization, UNICEF, the World Bank, national governments from both donor and recipient countries, vaccine manufacturers from developed and emerging economies, research institutions, civil society organizations, and later, additional private sector partners. This structure was deliberately designed to leverage the comparative advantages of each sector: governments providing policy frameworks and delivery systems, manufacturers ensuring vaccine supply, UN agencies offering technical expertise and procurement mechanisms, and foundations bringing innovation capital.

The founding vision rested on several core insights. First, that vaccines represented one of the most cost-effective health interventions available, capable of preventing death and disability for pennies per dose. Second, that market failures in vaccine development and distribution could be corrected through coordinated global action and financial innovation. Third, that sustainable progress required not just short-term aid but long-term partnerships that built the capacity of national health systems. From the beginning, GAVI positioned itself not as a traditional donor but as a platform for collective action, pooling both financial resources and technical expertise to solve problems that no single actor could address alone.

GAVI's mission centers on saving children's lives and protecting people's health by increasing equitable access to vaccines in the world's poorest countries. The organization operates on the principle that a child's chance of being vaccinated should not depend on where they are born or how much money their family has. This commitment to equity drives every aspect of GAVI's work, from the selection of which vaccines to support to the design of financing mechanisms that ensure sustainability.

The Alliance employs a market-shaping approach that has fundamentally altered the economics of vaccine access. By aggregating demand from dozens of countries, GAVI creates predictable, high-volume markets that incentivize manufacturers to produce vaccines at lower prices. This pooled procurement model has driven down the cost of vaccines dramatically. Pentavalent vaccine, which protects against five diseases, has seen its price fall by more than 60 percent since GAVI's involvement, making it affordable for countries that previously could not consider introducing it. The organization also uses advance market commitments and other innovative financing tools to encourage the development of vaccines specifically for diseases that primarily affect low-income populations.

GAVI operates through a co-financing model that requires recipient countries to contribute to the cost of their vaccines, with the share gradually increasing as national income grows. This approach ensures countries have ownership of their immunization programs while building toward long-term sustainability. Countries begin by paying as little as 20 cents per dose, with contributions rising over time until they can fully finance their own vaccine programs and transition out of GAVI support. This graduation process has seen several countries, including Indonesia and several nations in Latin America, successfully transition to self-financing, demonstrating the model's effectiveness in building sustainable health systems.

The organization's strategy extends beyond simply purchasing vaccines. GAVI provides comprehensive support for strengthening immunization systems, including cold chain equipment to keep vaccines at proper temperatures, training for healthcare workers, community outreach to build trust and demand, and data systems to track coverage and identify gaps. This holistic approach recognizes that vaccines only save lives when they reach the children who need them, requiring robust delivery infrastructure and community engagement alongside the vaccines themselves.

GAVI's portfolio spans vaccines against some of childhood's deadliest diseases. The Alliance has supported immunization against pneumococcal disease, which causes pneumonia and meningitis and was responsible for hundreds of thousands of child deaths annually before vaccines became widely available in poor countries. GAVI has also expanded access to rotavirus vaccines, dramatically reducing deaths from severe diarrhea, and supported the introduction of vaccines against measles, rubella, and human papillomavirus, which causes cervical cancer. Each vaccine introduction represents years of planning, supply negotiations, health system strengthening, and community mobilization.

The scale of GAVI's impact becomes clear through the numbers. The Alliance reports that since 2000, it has helped immunize more than a billion children across 73 of the world's poorest countries. Epidemiological modeling suggests these immunizations have prevented more than 17 million future deaths. Coverage rates for basic vaccines have increased substantially in GAVI-supported countries, with the gap between rich and poor nations narrowing significantly. These statistics represent individual children who grew up free from disability, families spared the tragedy of preventable loss, and communities able to thrive without the burden of epidemic disease.

One of GAVI's most significant achievements has been accelerating the introduction of new vaccines in developing countries. Historically, it took 15 to 20 years for new vaccines to reach the poorest nations after their introduction in wealthy countries. GAVI has compressed this timeline to just a few years for many vaccines, ensuring that children everywhere benefit from scientific advances rather than waiting a generation. This acceleration has been particularly important for pneumococcal and rotavirus vaccines, which address diseases that disproportionately affect children in low-resource settings.

GAVI's support has also been crucial during health emergencies. During the Ebola outbreak in West Africa, the Alliance helped fund the development and deployment of an effective Ebola vaccine. More recently, GAVI serves as a key delivery partner for COVAX, the global initiative to ensure equitable access to COVID-19 vaccines, applying its expertise in procurement, supply chain management, and country support to the pandemic response. This work has extended GAVI's reach beyond children to include healthcare workers and vulnerable adults, demonstrating the flexibility of the alliance model.

GAVI's field operations are built on partnership with national governments, which maintain ownership and leadership of their immunization programs. Each country interested in GAVI support submits an application outlining its immunization needs, existing coverage rates, plans for introducing new vaccines, and strategies for reaching underserved populations. This application process ensures that support aligns with national health priorities and builds on existing systems rather than creating parallel structures. Technical partners, including WHO and UNICEF, work with countries to develop robust applications and implementation plans.

Once support is approved, GAVI works through established UNICEF procurement mechanisms to purchase vaccines at negotiated prices, ensuring quality and reliability of supply. Countries receive vaccines along with financial support for operational costs, including distribution, staff training, and community mobilization. GAVI also provides funding for health system strengthening, recognizing that effective immunization requires more than just vaccines. This might include cold chain equipment that maintains vaccines at safe temperatures from the national warehouse to the most remote health post, motorbikes or vehicles for vaccine transport and supervision, or solar refrigerators for areas without reliable electricity.

In the field, vaccination typically happens through a combination of fixed health facilities and outreach services. Health workers conduct routine immunization sessions at clinics and health posts, while mobile teams venture into remote areas, sometimes traveling for days to reach isolated communities. Community health workers play a vital role in educating families about the importance of vaccination, maintaining registries of children due for vaccines, and following up with those who miss appointments. GAVI support enables these workers to have the training, tools, and resources they need to do their jobs effectively.

Monitoring and evaluation are integral to GAVI's field operations. Countries report coverage data, vaccine stock levels, and program performance regularly. GAVI uses this information to identify challenges early, from supply chain bottlenecks to declining coverage in specific regions, and to provide targeted technical assistance. Partners conduct periodic reviews to assess program quality and identify opportunities for improvement. This data-driven approach allows for course corrections and ensures that resources reach those who need them most. When challenges emerge, whether logistical, political, or social, GAVI and its partners work with countries to develop solutions that address local contexts while maintaining program integrity.

GAVI operates in 73 of the world's poorest countries, home to more than half of the world's children. This geographic reach spans sub-Saharan Africa, where vaccine-preventable diseases have historically taken the highest toll, South and Southeast Asia with its vast populations and challenging logistics, and pockets of vulnerability in other regions. The Alliance's work has contributed to broader progress toward global health goals, including the United Nations Sustainable Development Goals, particularly those related to child mortality, health equity, and strengthening health systems.

The organization's innovative financing model has attracted attention from development economists and public health experts as a template for addressing other global challenges. By demonstrating how to align incentives across diverse stakeholders, create sustainable markets for global public goods, and build country ownership through co-financing, GAVI has influenced thinking about international development cooperation more broadly. The Alliance has received support from governments of both wealthy donor nations and emerging economies, major philanthropies, and private sector partners who see vaccines as both a moral imperative and a foundation for social and economic development.

GAVI's governance structure reflects its partnership model. The organization's board includes representatives from donor and recipient governments, vaccine manufacturers from both developed and developing countries, civil society, independent experts, and the founding partner organizations. This diverse composition ensures that decision-making incorporates multiple perspectives and that the Alliance remains accountable to all stakeholders, particularly the countries and communities it serves. Regular independent evaluations assess GAVI's performance, efficiency, and impact, contributing to transparency and continuous improvement.

As GAVI looks toward the future, it faces both opportunities and challenges. The Alliance must navigate an evolving landscape that includes new vaccine technologies, emerging infectious diseases, growing vaccine hesitancy in some populations, the impacts of climate change on disease patterns and health systems, and the need to reach the most marginalized children who have been missed by routine services. Yet GAVI's track record demonstrates the power of sustained partnership and strategic investment. By proving that equity in vaccine access is achievable, the Alliance has not only saved millions of lives but also expanded our understanding of what global cooperation can accomplish when diverse actors unite around a shared purpose.